MX377714B - Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a. - Google Patents
Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.Info
- Publication number
- MX377714B MX377714B MX2016004736A MX2016004736A MX377714B MX 377714 B MX377714 B MX 377714B MX 2016004736 A MX2016004736 A MX 2016004736A MX 2016004736 A MX2016004736 A MX 2016004736A MX 377714 B MX377714 B MX 377714B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- ctla
- antibody
- vegf antagonist
- combination
- Prior art date
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000011122 anti-angiogenic therapy Methods 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892601P | 2013-10-18 | 2013-10-18 | |
| US201361901596P | 2013-11-08 | 2013-11-08 | |
| US201461952923P | 2014-03-14 | 2014-03-14 | |
| US201462055734P | 2014-09-26 | 2014-09-26 | |
| PCT/US2014/061071 WO2015058048A1 (en) | 2013-10-18 | 2014-10-17 | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004736A MX2016004736A (es) | 2016-07-26 |
| MX377714B true MX377714B (es) | 2025-03-11 |
Family
ID=51844874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004736A MX377714B (es) | 2013-10-18 | 2014-10-17 | Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9968674B2 (enExample) |
| EP (1) | EP3057990B1 (enExample) |
| JP (1) | JP6607850B2 (enExample) |
| KR (1) | KR102338453B1 (enExample) |
| CN (1) | CN105636986B (enExample) |
| AU (1) | AU2014337135B2 (enExample) |
| CA (1) | CA2926853C (enExample) |
| EA (1) | EA037890B1 (enExample) |
| IL (1) | IL244599B (enExample) |
| MX (1) | MX377714B (enExample) |
| WO (1) | WO2015058048A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
| EP2766043A4 (en) | 2011-10-13 | 2015-06-10 | Aerpio Therapeutics Inc | METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER |
| CN112626125A (zh) | 2014-03-17 | 2021-04-09 | 阿德夫拉姆生物技术股份有限公司 | 用于视锥细胞中增强的基因表达的组合物和方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| WO2017106462A1 (en) * | 2015-12-18 | 2017-06-22 | Biogen Ma Inc. | Bispecific antibody platform |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| IL279919B2 (en) * | 2016-06-16 | 2025-01-01 | Adverum Biotechnologies Inc | Treating AMD using an AAV2 variant with aflibercept |
| KR20190031246A (ko) | 2016-07-20 | 2019-03-25 | 에르피오 세러퓨틱스 인코포레이티드 | VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체 |
| IL307242A (en) | 2016-12-07 | 2023-11-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| WO2018144587A1 (en) * | 2017-01-31 | 2018-08-09 | Research Development Foundation | Steap2 inhibitors for the treatment of liver cancers |
| MA50908A (fr) | 2017-11-17 | 2020-09-23 | Amgen Inc | Formulations de protéines de fusion vegfr-fc |
| WO2019152423A1 (en) * | 2018-02-02 | 2019-08-08 | Oncoimmune, Inc. | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| CA3089704A1 (en) * | 2018-02-02 | 2019-08-08 | Oncoimmune, Inc. | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| JP2021514656A (ja) * | 2018-03-02 | 2021-06-17 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート |
| SG11202010589YA (en) | 2018-05-14 | 2020-11-27 | Oncoimmune Inc | Anti-cd24 compositions and uses thereof |
| CN113164597B (zh) | 2018-09-24 | 2025-02-28 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| BR112021008060A2 (pt) * | 2018-10-31 | 2021-11-23 | Bioatla Inc | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento |
| CN111378044B (zh) * | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
| AU2020216368B2 (en) * | 2019-01-30 | 2025-04-24 | Amgen Inc. | Aflibercept attributes and methods of characterizing and modifying thereof |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19802753A1 (de) * | 1998-01-26 | 1999-07-29 | Merck Patent Gmbh | Coreaktive Trägermaterialien zur Heterogenisierung von Katalysatoren, Cokatalysatoren und Liganden |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7303746B2 (en) * | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU784012B2 (en) | 1999-08-24 | 2006-01-12 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| CN101052655A (zh) * | 2004-11-04 | 2007-10-10 | 辉瑞产品有限公司 | 用于治疗乳腺癌的ctla4抗体和芳香酶抑制剂组合物 |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| EP2212432A4 (en) * | 2007-10-22 | 2011-10-19 | Schering Corp | COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES |
| EP2240204A1 (en) | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
-
2014
- 2014-10-17 JP JP2016524116A patent/JP6607850B2/ja active Active
- 2014-10-17 CN CN201480054902.1A patent/CN105636986B/zh active Active
- 2014-10-17 WO PCT/US2014/061071 patent/WO2015058048A1/en not_active Ceased
- 2014-10-17 KR KR1020167013164A patent/KR102338453B1/ko active Active
- 2014-10-17 CA CA2926853A patent/CA2926853C/en active Active
- 2014-10-17 MX MX2016004736A patent/MX377714B/es active IP Right Grant
- 2014-10-17 EP EP14792686.9A patent/EP3057990B1/en active Active
- 2014-10-17 US US15/026,460 patent/US9968674B2/en active Active
- 2014-10-17 EA EA201690633A patent/EA037890B1/ru unknown
- 2014-10-17 AU AU2014337135A patent/AU2014337135B2/en active Active
-
2016
- 2016-03-15 IL IL24459916A patent/IL244599B/en active IP Right Grant
-
2018
- 2018-04-23 US US15/959,595 patent/US10532096B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6607850B2 (ja) | 2019-11-20 |
| EA037890B1 (ru) | 2021-06-01 |
| WO2015058048A1 (en) | 2015-04-23 |
| KR20160067978A (ko) | 2016-06-14 |
| CN105636986A (zh) | 2016-06-01 |
| US10532096B2 (en) | 2020-01-14 |
| JP2016539096A (ja) | 2016-12-15 |
| US20180236070A1 (en) | 2018-08-23 |
| CN105636986B (zh) | 2020-05-12 |
| US20160243225A1 (en) | 2016-08-25 |
| AU2014337135B2 (en) | 2019-09-19 |
| IL244599A0 (en) | 2016-04-21 |
| EP3057990B1 (en) | 2019-09-04 |
| KR102338453B1 (ko) | 2021-12-13 |
| US9968674B2 (en) | 2018-05-15 |
| CA2926853C (en) | 2022-04-26 |
| IL244599B (en) | 2019-10-31 |
| MX2016004736A (es) | 2016-07-26 |
| EP3057990A1 (en) | 2016-08-24 |
| EA201690633A1 (ru) | 2016-08-31 |
| CA2926853A1 (en) | 2015-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377714B (es) | Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a. | |
| CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
| CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
| PH12016501618A1 (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
| CR20140441A (es) | Anticuerpos anti-lgr5 e inmunoconjugados | |
| ZA201801957B (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
| ZA201801401B (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| MX2015017331A (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
| CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| CR20150047A (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| CO7151527A2 (es) | Anticuerpos anti-cd79 b e inmunoconjugados | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| MX375378B (es) | Formulaciones de anticuerpos anti-pdl1. | |
| EA201790334A1 (ru) | Конъюгаты анти-cdh6 антитела с лекарственным средством | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| HRP20190888T8 (hr) | Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma | |
| IN2014DN05885A (enExample) | ||
| MX2019015604A (es) | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia. | |
| MX2019005299A (es) | Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares. | |
| BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
| EP3316863A4 (en) | DIRECTED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |